GlassScriptPhysician profile
Victor Velazquez
NPI 1962402438
$2,299.98
in general payments reported to CMS, 2019-2025
15 companies · $846 in 2025
The $846 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $267 · 2022: $392 · 2023: $344 · 2024: $452 · 2025: $846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,641.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $722.72 | 2021-2023 | Wegovy, Saxenda |
| Lilly USA, LLC | $404.33 | 2023-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $278.89 | 2025 | Freestyle Libre 3 |
| Corium, LLC | $253.82 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $201.74 | 2023-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $127.41 | 2024-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Eisai INC. | $124.49 | 2024 | |
| Alk-Abello, INC | $47.35 | 2025 | Odactra, Ragwitek, Grastek |
| Glaxosmithkline, LLC. | $46.19 | 2022-2025 | Bexsero |
| Corcept Therapeutics | $26.62 | 2025 | Korlym |
| Ultragenyx Pharmaceutical INC. | $19.52 | 2023 | |
| Phadia US INC. | $18.25 | 2023 | Immunocap |
| Collegium Pharmaceutical, INC. | $14.54 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $11.51 | 2021 | |
| Genentech USA, INC. | $2.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Velazquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.